Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
29 Mayo 2024 - 6:00AM
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage
biotechnology company pioneering the development of a new class of
programmable epigenomic mRNA medicines, today announced the
appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr.
Certel brings to Omega extensive biopharmaceutical industry
experience and will be responsible for global business development
activities including strategic partnerships.
“Kaan is an accomplished biopharma executive with
deep expertise in business development and corporate strategy, and
I am delighted to welcome him to Omega’s executive team,” said
Mahesh Karande, President and Chief Executive Officer of Omega
Therapeutics. “His successful track record in forging strategic
partnerships, extensive experience in portfolio strategy,
leadership and his deep scientific grounding will be invaluable as
we build momentum in developing partnerships to advance our
proprietary OMEGA platform and pipeline of programmable epigenomic
mRNA therapeutics.”
Dr. Certel added, “I am thrilled to join Omega at
such a pivotal time in the Company’s journey towards advancing its
versatile approach to precision epigenomic control, which has the
potential to address nearly any human disease. The broad
applicability of the OMEGA platform provides many exciting
opportunities to create high-value strategic business partnerships.
I look forward to advancing our collaboration opportunities,
contributing to Omega’s corporate growth, and supporting our
mission to bring transformative new therapeutics to patients.”
Dr. Certel is a recognized business development
leader with over 20 years of experience in the biopharmaceutical
industry and academia. Most recently, he served as the Chief
Business Officer at BioCity Biopharma, where he led the expansion
of the global business development function and coordinated efforts
to establish collaborations for the development of pipeline assets.
Previously, Dr. Certel was the Global Head of Oncology External
Innovation at Sanofi, where he played a pivotal role in
strengthening the oncology portfolio by assessing in-licensing
opportunities and spearheading numerous strategic collaborations.
Notably, he also played a key role in the successful launch of
X-Chem Pharmaceuticals’ immuno-oncology spin-off, overseeing
scientific strategic development, pipeline generation, project
management and talent acquisition. Dr. Certel received a Ph.D. in
Genetics from the University of Iowa and completed a postdoctoral
fellowship at the Koch Institute for Integrative Cancer Research at
the Massachusetts Institute of Technology (MIT).
About Omega TherapeuticsOmega
Therapeutics is a clinical-stage biotechnology company pioneering
the development of a new class of programmable epigenomic mRNA
medicines to treat or cure a broad range of diseases. By
pre-transcriptionally modulating gene expression, Omega’s approach
enables precision epigenomic control of nearly all human genes,
including historically undruggable and difficult-to-treat targets,
without altering native nucleic acid sequences. Founded in 2017 by
Flagship Pioneering following breakthrough research by
world-renowned experts in the field of epigenetics, Omega is led by
a seasoned and accomplished leadership team with a track record of
innovation and operational excellence. The Company is committed to
revolutionizing genomic medicine and has a pipeline of therapeutic
candidates derived from its OMEGA platform spanning oncology,
regenerative medicine, and multigenic diseases including
inflammatory and cardiometabolic conditions.
For more information, visit omegatherapeutics.com,
or follow us on X and LinkedIn.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation statements surrounding the
potential of our development candidates, developing strategic
partnerships; and Dr. Certel’s impact on the Company. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: the novel
technology on which our product candidates are based makes it
difficult to predict the time and cost of preclinical and clinical
development and subsequently obtaining regulatory approval, if at
all; the substantial development and regulatory risks associated
with epigenomic controllers due to the novel and unprecedented
nature of this new category of medicines; our limited operating
history; the incurrence of significant losses and the fact that we
expect to continue to incur significant additional losses for the
foreseeable future; our need for substantial additional financing;
volatility in capital markets and general economic conditions; our
investments in research and development efforts that further
enhance the OMEGA platform, and their impact on our results;
uncertainty regarding preclinical development, especially for a new
class of medicines such as epigenomic controllers; potential delays
in and unforeseen costs arising from our clinical trials; the fact
that our product candidates may be associated with serious adverse
events, undesirable side effects or have other properties that
could halt their regulatory development, prevent their regulatory
approval, limit their commercial potential, or result in
significant negative consequences; difficulties manufacturing the
novel technology on which our epigenomic controller candidates are
based; our ability to adapt to rapid and significant technological
change; our reliance on third parties for the manufacture of
materials; our ability to successfully acquire and establish our
own manufacturing facilities and infrastructure; our reliance on a
limited number of suppliers for lipid excipients used in our
product candidates; our ability to advance our product candidates
to clinical development; and our ability to obtain, maintain,
enforce and adequately protect our intellectual property rights.
These and other important factors discussed under the caption “Risk
Factors” in our Quarterly Report on Form 10-Q for the quarter ended
March 31, 2024, and our other filings with the SEC, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
ContactInvestor
contact:Eva
Stroynowski617.949.4370estroynowski@omegatx.com
Media contact:Mollie
GodboutLifeSci
Communications646.847.1401mgodbout@lifescicomms.com
Omega Therapeutics (NASDAQ:OMGA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Omega Therapeutics (NASDAQ:OMGA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024